Viking Therapeutics to Present Phase 2 Weight Loss Data and Phase 3 Enrollment at ECO 2026
Viking Therapeutics will present 13-week Phase 2 VENTURE-Oral data showing significant weight loss and favorable tolerability for oral VK2735 at the European Congress on Obesity 2026. The company will detail enrollment demographics of the Phase 3 VANQUISH-1 study evaluating subcutaneous VK2735 in obese or overweight adults with weight-related comorbidities.
1. ECO 2026 Poster Presentations
Viking Therapeutics will present two posters at the 33rd European Congress on Obesity in Istanbul. The first highlights 13-week Phase 2 VENTURE-Oral data on oral VK2735, while the second outlines design and enrollment of the Phase 3 VANQUISH-1 subcutaneous trial.
2. Phase 2 VENTURE-Oral Trial Data
The VENTURE-Oral study evaluated oral VK2735 over 13 weeks in a randomized, placebo-controlled, dose-finding format. Key endpoints include statistically significant weight loss and tolerability, demonstrating potential for metabolic disorder treatment with the dual GLP-1/GIP agonist.
3. Phase 3 VANQUISH-1 Study Design
The ongoing VANQUISH-1 trial is enrolling obese or overweight adults with at least one weight-related comorbidity to assess subcutaneous VK2735 efficacy. Enrollment demographics emphasize diversity, aiming to evaluate treatment response across varied populations.